United Therapeutics
UTHR
850 hedge funds and large institutions have $24.6B invested in United Therapeutics in 2026 Q1 according to their latest regulatory filings, with 111 funds opening new positions, 300 increasing their positions, 322 reducing their positions, and 83 closing their positions.
63% more funds holding in top 10
Funds holding in top 10: 16 → 26 (+10)
34% more first-time investments, than exits
New positions opened: 111 | Existing positions closed: 83
21% more capital invested
Capital invested by funds: $20.3B → $24.6B (+$4.28B)
2% more funds holding
Funds holding: 837 → 850 (+13)
4% more call options, than puts
Call options by funds: $1.21B | Put options by funds: $1.17B
7% less repeat investments, than reductions
Existing positions increased: 300 | Existing positions reduced: 322
2.23% less ownership
Funds ownership: 96.94% → 94.71% (-2.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$114M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$86.4M |
| 3 |
Fifth Third Bancorp
Cincinnati,
Ohio
|
+$81.9M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$63.3M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
-$227M |
| 2 |
Jane Street
New York
|
-$107M |
| 3 |
D.E. Shaw & Co
New York
|
-$104M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$88.3M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$83.6M |
UTHR Hedge Fund Activity: Q1 2026 in Review
850 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q1 2026, worth a combined $24.6B — up 21% from $20.3B a quarter earlier.
Buyers outnumbered sellers: 111 funds opened new UTHR positions and 83 closed out — a net gain of 28 holders — while 300 added to existing stakes and 322 trimmed.
The largest buyer was BlackRock, adding an estimated $114M. The largest seller was AQR Capital Management, cutting an estimated $227M.
- 850 institutional investors held United Therapeutics (UTHR) as of Q1 2026, up from 837 in Q4 2025.
- Funds reported $24.6B of United Therapeutics stock for Q1 2026, up 21% quarter-over-quarter.
- 111 funds opened new United Therapeutics positions in Q1 2026 and 83 closed out, a net change of +28 holders.
- The largest United Therapeutics buyer in Q1 2026 was BlackRock, an estimated $114M added.
- The largest United Therapeutics seller in Q1 2026 was AQR Capital Management, an estimated $227M sold.
Based on aggregated 13F filings for Q1 2026.